Mitotane in adrenocortical carcinoma: a profile of its use

Abstract The adrenal cytotoxic agent mitotane (Lysodren ® ) has a central role in the systemic treatment of adrenocortical carcinoma (ACC), rare and aggressive cancer glands. Although its precise mechanism action remains unclear, been evaluated used for more than 60 years and, to date, is only drug specifically approved ACC. ACC continues be associated with poor prognosis, shown provide clinically significant benefit good proportion patients treated drug, both advanced (unresectable/metastatic) disease adjuvant therapy settings. While generally manageable tolerability most adverse events (including neurotoxicity) being reversible dose reduction or interruption, regular monitoring plasma concentrations during important help ensure optimal use while minimising impact toxicity.